DelveInsight launched its new report on Hypercholesterolemia – Market Insights, Epidemiology, and Market Forecast-2030.
DelveInsight’s “Hypercholesterolemia – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Hypercholesterolemia, historical and forecasted epidemiology as well as the Hypercholesterolemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some key facts of the report:
More than 34 million American adults have increased blood cholesterol levels (i.e. higher than 240 mg/dL).
Key benefits of the report:
1. Hypercholesterolemia market report covers a descriptive overview and comprehensive insight of the Hypercholesterolemia epidemiology and Hypercholesterolemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Hypercholesterolemia market report provides insights into current and emerging therapies.3. Hypercholesterolemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Hypercholesterolemia market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Hypercholesterolemia market.
Request for sample pages: https://www.delveinsight.com/sample-request/hypercholesterolemia-market
Hypercholesterolemia is the most commonly occurring disorder, which results in comorbid conditions, mainly cardiovascular disorders. High levels of low-density lipoprotein (LDL) cholesterol results into an accumulation of cholesterol-rich fatty deposits in arteries resulting in a narrow or blocked flow of blood to vital organs, especially the heart and brain.
The Hypercholesterolemia treatment paradigm, which further includes sub-types, such as Homozygous and Heterozygous Familial Hypercholesterolemia holds several options available in the market, i.e., statins, bile-acid-binding resins, cholesterol absorption inhibitors, combination cholesterol absorption inhibitor with statin and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors as well as Injectable medications.
Key pharma players involved in Hypercholesterolemia market are:
1. Innovent Biologics2. Esperion3. Regeneron Pharmaceuticals4. Akcea Therapeutics5. Ionis Pharmaceuticals
Drugs covered are:1. IBI3062. Bempedoic Acid3. AKCEA-ANGPTL3-LRX4. Evinacumab
Table of contents:1. Report Introduction2. Hypercholesterolemia Market Overview at a Glance3. Hypercholesterolemia Disease Background and Overview4. Hypercholesterolemia Epidemiology and Patient Population (7MM)5. Hypercholesterolemia Country-Wise Epidemiology5.1. United States5.2. EU5 Countries5.3. Germany5.4. France5.5. Italy5.6. Spain5.7. United Kingdom5.8. Japan6. Hypercholesterolemia Treatments and Medical Practices7. Hypercholesterolemia Current Treatment7.1. Repatha: Amgen7.2. Praluent: Sanofi7.3. Lipitor: Pfizer8. Hypercholesterolemia Emerging Therapies8.1. Key Cross Competition8.2. IBI306: Innovent Biologics8.3. Bempedoic Acid: Esperion8.4. Evinacumab: Regeneron Pharmaceuticals8.5. AKCEA-ANGPTL3-LRX: Akcea Therapeutics/Ionis Pharmaceuticals9. Hypercholesterolemia Market Size10. Hypercholesterolemia 7MM Country-Wise Market Analysis11. United States Market Size12. EU5 Market Size12.1. Germany Market Size12.2. France Market Size12.3. Italy Market Size12.4. Spain Market Size12.5. United Kingdom Market Size13. Japan Market Size14. Market Drivers15. Market Barriers16. Report Methodology17. DelveInsight Capabilities18. Disclaimer19. About DelveInsight
Related reports:
Hypercholesterolemia – Epidemiology Forecast to 2030
Hypercholesterolemia Pipeline Insight, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/